Neurocrine Biosciences upgraded at Wells Fargo on pipeline [Seeking Alpha]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Seeking Alpha
The firm also upped its price target to $170 from $140 (~21% upside based on April 23 close). Analyst Mohit Bansal believes that the company's crinecerfont, in phase 3 for two neuroendocrinology indications, could propel Neurocrine into a large-cap stock. He calls the asset underappreciated and believes it could be a $1.5B peak sales drug, compared to $500M-$700M estimates from the Street. Bansal noted that crinecerfont could command a price of $200,000 per year. Elsewhere in the pipeline, Bansal is "cautiously optimistic" on NBI-1117568, a muscarinic agent in phase 2 for schizophrenia. Currently, he sees a 35% chance of success in this phase. Positive data could see the stock go up $25/share, while negative data could lead to a $25/share decline. He also sees promise with phase 2 depression candidate NBI-1065845. While the asset works in a similar fashion to Johnson & Johnson's ( JNJ ) Spravato (esketamine) and Axsome Therapeutics ( AXSM ) Auvelity (dextromethorphan and bupr
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Celonis Appoints Mark Jacobs as Go-to-Market Leader for North America [Yahoo! Finance]Yahoo! Finance
- Phase 2 data for ERLEADA® ?(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100 percent biochemical free recurrence rate more than two years post-surgery [Yahoo! FinYahoo! Fin
- Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery [Yahoo! Finance]Yahoo! Finance
- TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer [Yahoo! Finance]Yahoo! Finance
- TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 5/3/24 - Form 4
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- JNJ's page on the SEC website